For unresectable Hepatocellular carcinoma (HCC), chemotherapy is still an important
treatment strategy. Oxaliplatin (Oxa) is an effective treatment of HCC after sorafenib …

Yes‑associated protein (YAP) serves an essential role in tumorigenesis. However, the
potential role and the molecular mechanism underlying the effect of YAP on hepatocellular …

Hepatocellular carcinoma (HCC) is one of the most aggressive malignancies worldwide and
is highly resistant to chemotherapy. Yes-associated protein (YAP) is the downstream effector …

Liver cancer has relatively few early symptoms and is usually diagnosed in the advanced
stage. Sorafenib is the only first-line anticancer drug approved by the Food and Drug …

Abstract In China, Trametes robiniophila Murr (Huaier), a traditional Chinese herbal
medicine, has been widely used in adjuvant therapies of hepatocellular carcinoma (HCC) …

Background Sorafenib is the standard first-line treatment for advanced hepatocellular
carcinoma (HCC), but its use is hampered by secondary drug resistance. Yes-associated …

Hepatocellular carcinoma (HCC) is one of the most lethal malignancies worldwide.
However, the immune tolerance limits the effect of chemotherapeutic drugs. Therefore, the …

Background Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related
deaths worldwide. Sorafenib is the first-line treatment for advanced HCC, but the anti-cancer …

Background Multi-drug resistance is the major cause of chemotherapy failure in
hepatocellular carcinoma (HCC). YAP, a critical effector of the Hippo pathway, has been …

Background Yes-associated protein (YAP) is upregulated in many cancer types, and its
overexpression is involved in tumor cell proliferation, metastasis and resistance to …